Dr. John Marshall presents the Avastin MCRC pivotal trials. Follow a hypothetical patient through first- and second-line treatment with Avastin.
FDA Grants Priority Review to NDA of Fruquintinib for Metastatic CRC
If granted approval, fruquintinib will be the first and only highly selective inhibitor of all 3 VEGF receptors to be approved in the United States for patients with metastatic colorectal cancer.
Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers
In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer
SunRISE Program Incites Optimism About the Future of High-Risk, BCG-Unresponsive NMIBC Treatment
In an interview with Targeted Oncology, Siamak Daneshmand, MD, discussed TAR-200 as seen in the SunRISE-1 trial and the what is up next for the treatment landscape of high-risk BCG-unresponsive non-muscle invasive bladder cancer.
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Multiple Factors at Play in the Rise of Early-Onset Colorectal Cancer
Oncologists are seeing early onset colorectal cancer more frequently, according to Jalal S. Baig, MD.
Updates to NCCN Guidelines for CNS Cancers Pinpoint the Importance of Testing
In an interview with Targeted Oncology, Craig Horbinski, MD, PhD, discussed recent recommendations and NCCN guidelines regarding the molecular profiling of gliomas and other central nervous system cancers.
2 Clarke Drive Cranbury, NJ 08512